Condition: B-cell Acute Lymphoblastic Leukemia · Large B-cell Lymphoma · Chronic Lymphocytic Leukemia · Sponsor: Vironexis Biotherapeutics Inc.
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
This description comes directly from the study's public registry record.
Allen Reha · 908-938-6019 · allen.reha@vironexis.com
Recruitment Partner: PatientWing · 213-459-2979 · studies@patientwing.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| New York Medical College | Valhalla, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill/ University of North Carolina Medical Center | Chapel Hill, North Carolina, United States | Recruiting |
| The Ohio State University Wexner Medical Center | Columbus, Ohio, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| TriStar BMT | Nashville, Tennessee, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06533579